Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies

Introduction
The efficacy of guselkumab versus adalimumab for psoriasis remains controversial.

Aim
We conducted a systematic review and meta-analysis to explore the influence of guselkumab versus adalimumab on treatment efficacy for psoriasis.

Material and methods
We have searched PubMed, Embase, Web of Science, EBSCO, and Cochrane library databases for randomized controlled trials (RCTs) published until March 2021 and assessing the efficacy and safety of guselkumab versus adalimumab for psoriasis. This meta-analysis was performed using the random-effects model.

Results
Three RCTs were included in the meta-analysis. Overall, compared with adalimumab for psoriasis, guselkumab was associated with improved PASI 100 (OR = 2.18; 95% CI: 1.47 to 3.23; p = 0.0001), PASI 90 (OR = 2.63; 95% CI: 2.11 to 3.27; p < 0.00001), PASI 75 (OR = 3.10; 95% CI: 2.35 to 4.08; p < 0.00001) and PGA 0/1 (OR = 2.04; 95% CI: 1.26 to 3.31; p = 0.004), as well as decreased DLQI (SMD = –0.24; 95% CI: –0.34 to –0.13; p < 0.00001). In addition, guselkumab resulted in higher DLQI score 0/1 (OR = 1.88; 95% CI: 1.51 to 2.33; p < 0.00001) than adalimumab.

Conclusions
Guselkumab showed better efficacy than adalimumab for psoriasis.